Phospho-CCND1 (Ser90) Antibody

What is Phospho-Cyclin D1 (Ser90) Antibody and what does it specifically detect?

Phospho-Cyclin D1 (Ser90) Antibody is a specialized immunological reagent designed to detect endogenous levels of Cyclin D1 protein only when it is phosphorylated at the Serine 90 position . This site-specific phosphorylation represents an important post-translational modification that affects Cyclin D1 function and stability. The antibody is typically generated in rabbits as a polyclonal antibody and purified through affinity chromatography using epitope-specific phosphopeptides . Non-phospho specific antibodies are removed through chromatography using non-phosphopeptides to ensure high specificity .

The immunogen used for generating these antibodies is commonly a synthetic phosphopeptide containing the sequence around the phosphorylation site of serine 90 (F-L-S(p)-L-E) derived from human Cyclin D1, often conjugated to KLH (Keyhole Limpet Hemocyanin) as a carrier protein . This careful production process ensures the antibody's specificity for the phosphorylated form of Cyclin D1 at Ser90.

What is the biological significance of Cyclin D1 phosphorylation at Ser90?

Cyclin D1 (also known as PRAD-1 or bcl-1) is a key cell cycle regulator that functions primarily by associating with cyclin-dependent kinases 4 and 6 (CDK4/CDK6) to phosphorylate the retinoblastoma (Rb) protein . Phosphorylation at Ser90 represents an important regulatory mechanism that affects Cyclin D1 stability and function.

While phosphorylation at Thr286 has been well-characterized as triggering ubiquitin-mediated degradation, the specific role of Ser90 phosphorylation is less extensively documented but appears to be involved in:

• Regulating protein-protein interactions with CDK partners

• Influencing subcellular localization of Cyclin D1

• Potentially modulating Cyclin D1's oncogenic properties

The site-specific phosphorylation status serves as a molecular switch that helps coordinate the temporal progression of the cell cycle, particularly the transition from G1 to S phase .

What are the primary research applications for Phospho-Cyclin D1 (Ser90) Antibody?

Phospho-Cyclin D1 (Ser90) Antibody has several validated research applications:

• Western Blotting (WB): The most common application, allowing quantitative analysis of phosphorylated Cyclin D1 levels in cell or tissue lysates

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection in solution-based samples

• Immunofluorescence (IF): For visualizing subcellular localization of phosphorylated Cyclin D1

• Immunocytochemistry (ICC): For detection in cultured cells

The antibody typically demonstrates cross-reactivity with human, mouse, and rat samples, with some products also showing predicted reactivity with pig, bovine, rabbit, and dog samples . When selecting an antibody for your specific application, it's essential to review the validation data for the particular species and technique you plan to use.

How does expression of phosphorylated Cyclin D1 correlate with clinicopathological features in cancer?

Research on thyroid cancer has revealed significant correlations between phosphorylated Cyclin D1 expression and various clinicopathological features. The data below summarizes key findings from a comprehensive study:

These findings suggest that phosphorylated Cyclin D1 may serve as a potential biomarker for more aggressive disease behavior, particularly in relation to metastatic potential and advanced staging in certain cancers . Researchers should consider evaluating both nuclear and cytoplasmic expression patterns, as the subcellular localization appears to have distinct clinical implications.

What methodological considerations are important when using Phospho-Cyclin D1 (Ser90) Antibody in Western blotting?

When using Phospho-Cyclin D1 (Ser90) Antibody in Western blotting experiments, several methodological considerations are crucial for obtaining reliable and reproducible results:

• Sample preparation:

  • Use phosphatase inhibitors during sample preparation to prevent dephosphorylation

  • Fresh preparation of lysates is preferred, as freeze-thaw cycles can affect phosphorylation status

  • Consider using synchronized cell populations when studying cell cycle-related phosphorylation events

• Controls:

  • Include both phosphorylated (positive) and non-phosphorylated (negative) controls

  • Consider using lysates from cells treated with phosphatase inhibitors as positive controls

  • Samples treated with lambda phosphatase can serve as negative controls

• Blocking and antibody conditions:

  • Optimal dilution typically ranges from 1:500 to 1:1000 for Western blotting

  • Use 5% BSA rather than milk for blocking and antibody dilution, as milk contains phospho-proteins that may interfere with detection

  • Longer primary antibody incubation (overnight at 4°C) often yields better results for phospho-specific antibodies

• Detection:

  • The expected molecular weight of Cyclin D1 is approximately 31-33 kDa

  • Consider using a total Cyclin D1 antibody on parallel blots to assess the proportion of phosphorylated protein

These methodological considerations help ensure specific detection of phosphorylated Cyclin D1 while minimizing background and non-specific binding.

How can researchers distinguish between different phosphorylation sites on Cyclin D1?

Cyclin D1 contains multiple phosphorylation sites, with Ser90 and Thr286 being among the most studied. Distinguishing between these sites requires careful experimental design:

• Site-specific antibodies: Use antibodies that specifically recognize distinct phosphorylation sites, such as Phospho-Cyclin D1 (Ser90) and Phospho-Cyclin D1 (Thr286) antibodies

• Functional validation approaches:

  • Site-directed mutagenesis: Create S90A or T286A mutants to prevent phosphorylation at specific sites

  • Kinase inhibition studies: Use inhibitors of specific kinases known to phosphorylate different sites

  • Phosphatase treatment: Differential sensitivity to specific phosphatases can help distinguish sites

• Mass spectrometry analysis:

  • Provides definitive identification and quantification of phosphorylation at specific residues

  • Can be combined with immunoprecipitation using total Cyclin D1 antibodies

• Combined detection methods:

  • Sequential probing with different phospho-specific antibodies

  • Comparison with total Cyclin D1 levels

Each phosphorylation site on Cyclin D1 may have distinct functional consequences. For example, phosphorylation at Thr286 is known to trigger ubiquitin-mediated degradation and G1/S phase arrest , while Ser90 phosphorylation may have different regulatory effects.

What is known about the diagnostic utility of Cyclin D1 phosphorylation in differentiating thyroid cancer subtypes?

Research has revealed interesting patterns regarding Cyclin D1 expression and phosphorylation in thyroid cancer classification:

• Nuclear vs. Cytoplasmic Expression: Nuclear expression of Cyclin D1b protein shows significant diagnostic utility in distinguishing invasive encapsulated follicular variant of papillary thyroid carcinoma (PTC) from noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) .

• Comparative expression patterns:

• Correlation with genetic alterations: While BRAF V600E mutations were not found in either NIFTP or invasive encapsulated follicular variant PTC, one case of noninvasive encapsulated PTC with predominantly follicular growth showed both BRAF V600E mutation and positive cyclin D1b immunostaining .

• Relationship to TCGA dataset findings: High expression of CCND1 mRNA correlates with BRAF-like cancer (p < 0.001), though no direct association between CCND1 mRNA expression and clinicopathologic features was found in TCGA dataset analysis .

These findings suggest that phosphorylated Cyclin D1, particularly its nuclear localization, may have diagnostic value in distinguishing certain thyroid cancer subtypes, potentially complementing existing molecular classification approaches.

What experimental strategies can researchers employ to study the functional consequences of Cyclin D1 Ser90 phosphorylation?

To investigate the functional significance of Cyclin D1 Ser90 phosphorylation, researchers can employ several advanced experimental strategies:

• Phosphomimetic and phospho-deficient mutants:

  • Generate S90A (cannot be phosphorylated) and S90D/S90E (phosphomimetic) mutants

  • Express these in cell lines with CCND1 knockout background

  • Analyze effects on cell cycle progression, proliferation, and interaction with binding partners

• Identification of kinases and phosphatases:

  • Perform kinase/phosphatase inhibitor screens to identify enzymes regulating Ser90 phosphorylation

  • Use in vitro kinase assays with recombinant Cyclin D1 and candidate kinases

  • Apply proximity ligation assays to detect interactions between Cyclin D1 and regulatory enzymes

• Temporal dynamics studies:

  • Synchronize cells and analyze Ser90 phosphorylation throughout the cell cycle

  • Use live-cell imaging with phospho-specific antibodies or FRET-based sensors to track real-time phosphorylation changes

• Downstream pathway analysis:

  • Compare gene expression profiles between cells expressing wild-type vs. S90A/S90D Cyclin D1

  • Analyze changes in CDK4/6 activity and Rb phosphorylation status

  • Study effects on specific target genes and cellular functions

• Disease model applications:

  • Develop in vitro cancer models with altered Ser90 phosphorylation

  • Evaluate the impact on tumor growth, metastasis, and response to CDK4/6 inhibitors

  • Correlate findings with patient sample data on phosphorylation status and clinical outcomes

These experimental approaches provide a framework for comprehensive investigation of how Ser90 phosphorylation influences Cyclin D1 function in normal physiology and disease states.

What are the optimal storage and handling conditions for Phospho-Cyclin D1 (Ser90) Antibody?

Proper storage and handling of Phospho-Cyclin D1 (Ser90) Antibody is critical for maintaining its specificity and activity:

• Long-term storage:

  • Store at -20°C for up to one year

  • Antibodies are typically supplied in formulations containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide to maintain stability

• Short-term storage and working solutions:

  • For frequent use, store at 4°C for up to one month

  • Avoid repeated freeze-thaw cycles as they can degrade antibody quality and reduce specificity

  • When preparing working dilutions, use fresh buffer containing protease inhibitors

• Handling precautions:

  • Always wear gloves when handling antibodies

  • Centrifuge briefly before opening vials to ensure all liquid is at the bottom

  • Use sterile pipette tips and containers to prevent contamination

• Reconstitution (if applicable):

  • Follow manufacturer's specific instructions for reconstituting lyophilized antibodies

  • Document date of reconstitution and proper storage conditions

Following these storage and handling guidelines helps maintain antibody performance and extends its useful life.

How can researchers troubleshoot weak or non-specific signals when using Phospho-Cyclin D1 (Ser90) Antibody?

When encountering weak signals or high background with Phospho-Cyclin D1 (Ser90) Antibody, consider these troubleshooting approaches:

• Weak or no signal issues:

  • Verify phosphorylation state: Ensure your experimental conditions promote Ser90 phosphorylation

  • Increase antibody concentration: Try using a higher concentration within recommended range

  • Enhance signal detection: Consider using more sensitive detection systems or signal amplification methods

  • Optimize sample preparation: Use fresh samples and verify protein extraction efficiency

  • Confirm target expression: Validate Cyclin D1 expression using total Cyclin D1 antibody

• High background or non-specific binding:

  • Optimize blocking: Increase blocking time or try different blocking agents (BSA vs. serum)

  • Adjust antibody concentration: Dilute primary and secondary antibodies appropriately

  • Increase washing: Add additional wash steps with higher detergent concentration

  • Pre-adsorb antibody: Incubate antibody with negative control lysates to remove non-specific binders

  • Use phospho-peptide competition: Confirm specificity by comparing signals with and without competing phospho-peptide

• Multiple bands or unexpected band sizes:

  • Verify degradation: Check for proteolytic degradation by using fresh samples with protease inhibitors

  • Assess post-translational modifications: Multiple bands may represent different modified forms

  • Confirm antibody specificity: Test antibody on positive and negative control samples

  • Optimize gel percentage: Adjust acrylamide percentage to better resolve proteins in your molecular weight range

These strategies help address common technical challenges when working with phospho-specific antibodies.

How can Phospho-Cyclin D1 (Ser90) Antibody be used in cancer research and potential therapeutic development?

Phospho-Cyclin D1 (Ser90) Antibody offers valuable applications in cancer research and therapeutic development:

• Biomarker development:

  • Ser90 phosphorylation patterns correlate with lymph node metastasis and advanced disease stage in thyroid cancer

  • Potential use as a prognostic or predictive biomarker for treatment response

  • Differential expression between cancer subtypes suggests diagnostic applications

• Therapeutic target assessment:

  • Monitor changes in phosphorylation status following treatment with CDK inhibitors

  • Identify patients likely to respond to cell cycle-targeted therapies

  • Develop combination approaches targeting both Cyclin D1 expression and phosphorylation

• Mechanistic studies:

  • Investigate resistance mechanisms to CDK4/6 inhibitors

  • Study cross-talk between Cyclin D1 and other oncogenic pathways

  • Explore the relationship between different phosphorylation sites (Ser90 vs. Thr286)

• Emerging applications:

  • Integration with AI-based antibody design technology to develop more specific clinical-grade antibodies

  • Combination with spatial transcriptomics to map phosphorylation patterns in the tumor microenvironment

  • Development of phosphorylation-specific inhibitors targeting post-translational modifications

The continued refinement of phospho-specific antibodies and their application in multi-omics approaches will likely expand their utility in both basic research and clinical applications.

What is the significance of different subcellular localizations of phosphorylated Cyclin D1 in disease interpretation?

The subcellular localization of phosphorylated Cyclin D1 provides important insights into its function and disease relevance:

• Nuclear vs. cytoplasmic distribution:

  • Nuclear localization: Associated with transcriptional regulation and cell cycle progression

  • Cytoplasmic localization: May indicate altered trafficking or non-canonical functions

• Research findings on localization patterns:

  • In thyroid cancer studies, both nuclear and cytoplasmic expression patterns showed distinct correlations with clinicopathological features

  • Nuclear expression of cyclin D1b was significantly higher in invasive encapsulated follicular variant of PTC compared to NIFTP (p = 0.046)

  • Cytoplasmic expression showed a stronger correlation with gender (p = 0.040) and lymph node metastasis (p = 0.005)

• Methodological approaches for studying localization:

  • Immunofluorescence with subcellular markers

  • Cell fractionation followed by Western blotting

  • High-content imaging to quantify distribution patterns

• Functional implications:

  • Changes in localization may reflect altered protein interactions or modified function

  • Phosphorylation-dependent shuttling between compartments may represent a regulatory mechanism

  • Differential subcellular targeting could inform therapeutic approaches

Understanding the relationship between phosphorylation status and subcellular localization provides a more complete picture of Cyclin D1's role in normal physiology and disease states.

How do artificial intelligence approaches contribute to the development and application of phospho-specific antibodies?

Recent advances in artificial intelligence (AI) are transforming antibody research, including phospho-specific antibodies:

• AI-based antibody design:

  • De novo generation of antigen-specific antibody sequences using germline-based templates

  • Optimization of complementarity-determining regions (CDRs) for enhanced phospho-epitope recognition

  • Prediction of cross-reactivity and off-target binding

• Advantages of AI approaches:

  • Bypass traditional complex B cell processes while achieving similar specificity outcomes

  • More efficient and effective alternatives to experimental approaches for antibody discovery

  • Potential for rapid development of multiple variant-specific antibodies

• Application to phospho-epitopes:

  • Design of antibodies with enhanced discrimination between closely related phosphorylation sites

  • Development of antibodies recognizing specific conformational changes induced by phosphorylation

  • Creation of reagents for detecting patterns of multiple phosphorylation events

• Integration with experimental validation:

  • AI predictions require rigorous experimental validation

  • Iterative feedback between computational design and experimental testing

  • Combined approaches yield higher success rates and more specific antibodies

As AI technologies continue to advance, they will likely accelerate the development of next-generation phospho-specific antibodies with improved specificity, sensitivity, and versatility for complex research applications.